CoChat

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery

Open access

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Abstract

Recent updating of the World Health Organization (WHO) classification of central nervous system (CNS) tumors in 2016 demonstrates the first organized effort to restructure brain tumor classification by incorporating histomorphologic features with recurrent molecular alterations. Revised CNS tumor diagnostic criteria also attempt to reduce interobserver variability of histological interpretation and provide more accurate stratification related to clinical outcome. As an example, diffuse gliomas (WHO grades II-IV) are now molecularly stratified based upon isocitrate dehydrogenase 1 or 2 (IDH) mutational status, with gliomas of WHO grades II and III being substratified according to 1p/19q codeletion status. For now, grading of diffuse gliomas is still dependent upon histological parameters. Independent of WHO classification criteria, multidimensional scaling analysis of molecular signatures for diffuse gliomas from The Cancer Genome Atlas (TCGA) has identified distinct molecular subgroups, and allows for their visualization in 2-dimensional (2D) space. Using the web-based platform Oncoscape as a tool, we applied multidimensional scaling-derived molecular groups to the 2D visualization of the 2016 WHO classification of diffuse gliomas. Here we show that molecular multidimensional scaling of TCGA data provides 2D clustering that represents the 2016 WHO classification of diffuse gliomas. Additionally, we used this platform to successfully identify and define novel copy-number alteration-based molecular subtypes, which are independent of WHO grading, as well as predictive of clinical outcome. The prognostic utility of these molecular subtypes was further validated using an independent data set of the German Glioma Network prospective glioblastoma patient cohort.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-017-0443-7

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 2D multidimensional scaling plots of TCGA diffuse glioma patients based on genomic data. a Multidimensional scaling shows that there are three main clusters. b 2007 WHO histopathological classification across the three main clusters (number of cases for each cluster is listed). c WHO grades are shown across clusters (number of cases for each cluster is listed). d 3D representation of WHO grading, reflecting progression of each cluster
Fig. 1 2D multidimensional scaling plots of TCGA diffuse glioma patients based on genomic data. a Multidimensional scaling shows that there are three main clusters. b 2007 WHO histopathological classification across the three main clusters (number of cases for each cluster is listed). c WHO grades are shown across clusters (number of cases for each cluster is listed). d 3D representation of WHO grading, reflecting progression of each clusterCC BY · PubMed Central
Fig. 2 2D diffuse glioma plots with accompanying chromosomal ideograms. a The two main clusters on the right contain mutations in the IDH1 and IDH2 genes, as shown by the purple edges connecting the gene with corresponding patients. The IDH-mutant upper right cluster also carries the majority of (b) TP53 and (c) ATRX gene mutations. d The IDH-mutant lower right cluster contains gliomas that harbor the oligodendroglioma-specific 1p/19q codeletion, as demonstrated by orange edges connecting low level copy loss chromosomal regions with corresponding affected patients. This cluster also contains a majority of the IDH2 mutations
Fig. 2 2D diffuse glioma plots with accompanying chromosomal ideograms. a The two main clusters on the right contain mutations in the IDH1 and IDH2 genes, as shown by the purple edges connecting the gene with corresponding patients. The IDH-mutant upper right cluster also carries the majority of (b) TP53 and (c) ATRX gene mutations. d The IDH-mutant lower right cluster contains gliomas that harbor the oligodendroglioma-specific 1p/19q codeletion, as demonstrated by orange edges connecting low level copy loss chromosomal regions with corresponding affected patients. This cluster also contains a majority of the IDH2 mutationsCC BY · PubMed Central
Fig. 3 2D visualization of the revised 2016 WHO classification of diffuse gliomas. Multidimensional scaling demonstrates three major clusters of diffuse gliomas. The 2007 WHO histopathologic classifiers are heterogeneous and non-specific with regards to the three main clusters. The 2016 WHO classification aligns well with the three major clusters and can be divided into: 1) oligodendroglial tumors, IDH-mutant and 1p/19q-codeleted (WHO grades II–III); 2) astrocytic gliomas/glioblastomas, IDH-mutant (WHO grades II–IV); and 3) astrocytic gliomas/glioblastomas, IDH-wildtype (WHO grades II–IV)
Fig. 3 2D visualization of the revised 2016 WHO classification of diffuse gliomas. Multidimensional scaling demonstrates three major clusters of diffuse gliomas. The 2007 WHO histopathologic classifiers are heterogeneous and non-specific with regards to the three main clusters. The 2016 WHO classification aligns well with the three major clusters and can be divided into: 1) oligodendroglial tumors, IDH-mutant and 1p/19q-codeleted (WHO grades II–III); 2) astrocytic gliomas/glioblastomas, IDH-mutant (WHO grades II–IV); and 3) astrocytic gliomas/glioblastomas, IDH-wildtype (WHO grades II–IV)CC BY · PubMed Central
Fig. 4 Clinical characteristics of TCGA diffuse glioma clusters. a Survival curves from 2007 WHO histopathological classification criteria (A = diffuse astrocytoma, O = oligodendroglioma, OA = oligoastrocytoma, AA = anaplastic astrocytoma, AO = anaplastic oligodendroglioma, AOA = anaplastic oligoastrocytoma, GBM = glioblastoma). b Survival comparison of three main 2D molecular clusters. c-e Age at diagnosis distribution for each cluster. Patients with astrocytic glioma/glioblastoma are older at presentation in the (c) IDH-wildtype cluster than in the (d) IDH mutant cluster. e An apparent bimodal adult age distribution is seen in the oligodendroglioma cluster, with median age of 45 years. f Survival of patients with tumors of the oligodendroglioma cluster stratified by age (<45 versus ≥45 years) is significantly different (p = 0.0033), and comparable to survival stratified by WHO grade (g, h). P values determined using Cox proportional hazard regression
Fig. 4 Clinical characteristics of TCGA diffuse glioma clusters. a Survival curves from 2007 WHO histopathological classification criteria (A = diffuse astrocytoma, O = oligodendroglioma, OA = oligoastrocytoma, AA = anaplastic astrocytoma, AO = anaplastic oligodendroglioma, AOA = anaplastic oligoastrocytoma, GBM = glioblastoma). b Survival comparison of three main 2D molecular clusters. c-e Age at diagnosis distribution for each cluster. Patients with astrocytic glioma/glioblastoma are older at presentation in the (c) IDH-wildtype cluster than in the (d) IDH mutant cluster. e An apparent bimodal adult age distribution is seen in the oligodendroglioma cluster, with median age of 45 years. f Survival of patients with tumors of the oligodendroglioma cluster stratified by age (<45 versus ≥45 years) is significantly different (p = 0.0033), and comparable to survival stratified by WHO grade (g, h). P values determined using Cox proportional hazard regressionCC BY · PubMed Central
Fig. 5 Genomic copy number alteration frequency among molecular clusters. Oligodendrogliomas are defined by 1p/19q codeletion and the second most frequent alteration is loss of chromosome 4. The IDH-mutant astrocytic glioma/glioblastoma cluster has several low level copy number alterations, including known astrocytoma-associated alterations such as 9p loss and 19q loss. IDH-wildtype diffuse gliomas have frequent polysomy chromosome 7, chromosome 10 loss, and 9p loss. The IDH-wildtype cluster can be further divided into 3 subgroups (a–c). Subgroup A is separated from B and C by either the presence of polysomy chromosome 1 or TP53 mutations. Subgroups B and C are further separated by the presence or absence of polysomy chromosome 19
Fig. 5 Genomic copy number alteration frequency among molecular clusters. Oligodendrogliomas are defined by 1p/19q codeletion and the second most frequent alteration is loss of chromosome 4. The IDH-mutant astrocytic glioma/glioblastoma cluster has several low level copy number alterations, including known astrocytoma-associated alterations such as 9p loss and 19q loss. IDH-wildtype diffuse gliomas have frequent polysomy chromosome 7, chromosome 10 loss, and 9p loss. The IDH-wildtype cluster can be further divided into 3 subgroups (a–c). Subgroup A is separated from B and C by either the presence of polysomy chromosome 1 or TP53 mutations. Subgroups B and C are further separated by the presence or absence of polysomy chromosome 19CC BY · PubMed Central
Fig. 6 Diagnostic algorithm for 2D-mapping derived, copy number alteration-based, molecular subtypes of diffuse gliomas. Survival represent TCGA glioma dataset and P values were determined using Cox proportional hazard regression
Fig. 6 Diagnostic algorithm for 2D-mapping derived, copy number alteration-based, molecular subtypes of diffuse gliomas. Survival represent TCGA glioma dataset and P values were determined using Cox proportional hazard regressionCC BY · PubMed Central
Fig. 7 Multidimensional scale mapping derived copy number alterations forms unique prognostic molecular subtypes. a Glioblastoma, IDH-wildtype, WHO grade IV can be divided into three subtypes (W1–3). b The IDH-mutant astrocytic glioma/glioblastoma cluster can be divided into three molecular subtypes. These molecular subtypes are reflective of overall survival, and independent of WHO grade. c Dividing the molecular subtypes into either poor (M1/M2) or favorable (M3) groups is significantly associated with survival (Hazard ratio [HR] 3.28, 95% confidence interval [CI] 1.62–6.62, p = 0.001). This Hazard ratio is slightly larger, but comparable to dividing this cluster into WHO grade II versus WHO grade III/IV (HR 2.01, 95% CI 1.06–4.02, p = 0.036). P values determined using Cox proportional hazard regression
Fig. 7 Multidimensional scale mapping derived copy number alterations forms unique prognostic molecular subtypes. a Glioblastoma, IDH-wildtype, WHO grade IV can be divided into three subtypes (W1–3). b The IDH-mutant astrocytic glioma/glioblastoma cluster can be divided into three molecular subtypes. These molecular subtypes are reflective of overall survival, and independent of WHO grade. c Dividing the molecular subtypes into either poor (M1/M2) or favorable (M3) groups is significantly associated with survival (Hazard ratio [HR] 3.28, 95% confidence interval [CI] 1.62–6.62, p = 0.001). This Hazard ratio is slightly larger, but comparable to dividing this cluster into WHO grade II versus WHO grade III/IV (HR 2.01, 95% CI 1.06–4.02, p = 0.036). P values determined using Cox proportional hazard regressionCC BY · PubMed Central
Fig. 8 Prognostic validation of The Cancer Genome Atlas (TCGA) cluster-derived molecular subtypes in a large cohort from the German Glioma Network (GGN). a Bar graph showing normalized median overall survival (OS) compared to baseline with similar trends for TCGA and GGN datasets. b Linear regression analysis demonstrating equivalent ratio of normalized molecular subtype OS between TCGA and GGN data sets
Fig. 8 Prognostic validation of The Cancer Genome Atlas (TCGA) cluster-derived molecular subtypes in a large cohort from the German Glioma Network (GGN). a Bar graph showing normalized median overall survival (OS) compared to baseline with similar trends for TCGA and GGN datasets. b Linear regression analysis demonstrating equivalent ratio of normalized molecular subtype OS between TCGA and GGN data setsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 2

  1. Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G et al (2000) Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay area adult glioma study. Cancer 88:2342–2349 · DOI · Paper page
  2. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393 · doi:10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w

Cited by

See all 133

Metadata

Authors
Cimino, P. J., Zager, M., McFerrin, L., Wirsching, H.-G., Bolouri, H., Hentschel, B., von Deimling, A., Jones, D., Reifenberger, G., Weller, M., & Holland, E. C.
Affiliations
  • University of Washington (US)
  • Fred Hutch Cancer Center (US)
  • Leipzig University (DE)
  • University Hospital Heidelberg (DE)
  • German Cancer Research Center (DE)
  • University of Zurich (CH)
Corresponding author
  • Cimino, Patrick J.
  • Holland, Eric C.
Venue
Acta Neuropathologica Communications
Published
2017-05-22
Volume
5
Issue
1
Pages
39-39
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2618667624
Cited by
126
References
46
Citations by year
2026: 6 · 2025: 11 · 2024: 13 · 2023: 14 · 2022: 13 · 2021: 17 · 2020: 24 · 2019: 17 · 2018: 9 · 2017: 2
FWCI
8.17
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
Deutsche Krebshilfe (70-3163-Wi 3)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
diffuse glioma, WHO 2016 classification, multidimensional scaling, molecular subtypes, copy number alterations, IDH mutation, 1p/19q codeletion, glioblastoma, prognostic factors, central nervous system tumors
MeSH terms
Clinical Decision-Making, Adult, Algorithms, Brain Neoplasms, Glioma, Humans, Middle Aged, Prognosis, World Health Organization, Cohort Studies, Cluster Analysis, Survival Analysis, DNA Copy Number Variations, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. https://app.cochat.ai/papers/10.1186/s40478-017-0443-7
The paper
Cimino, P. J., Zager, M., McFerrin, L., Wirsching, H.-G., Bolouri, H., Hentschel, B., von Deimling, A., Jones, D., Reifenberger, G., Weller, M., & Holland, E. C. (2017). Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-017-0443-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.